Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
暂无分享,去创建一个
P. Erbs | J. Guitton | B. Klonjkowski | D. Tierny | C. Maurey | C. Machon | Isabelle Farine | J. Béguin | E. Laloy | Baptiste Moreau | J. Balloul | Sandrine Cochin | M. Gantzer | Christelle Pichon | E. Quéméneur | Johann Foloppe
[1] Liming Chen,et al. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis , 2022, Frontiers in Pharmacology.
[2] J. Pastor,et al. Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients , 2022, Veterinary sciences.
[3] G. Glikin,et al. Therapeutic potential of the cytosine deaminase::uracil phosphoribosyl transferase/5-fluorocytosine suicide system for canine melanoma. , 2021, Veterinary and comparative oncology.
[4] P. Erbs,et al. Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs , 2021, BMC Veterinary Research.
[5] Bin Zhang,et al. Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses , 2021, Frontiers in Oncology.
[6] G. Hutter,et al. Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs , 2021, Cancers.
[7] J. Foloppe,et al. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs , 2020, Scientific Reports.
[8] J. Foloppe,et al. Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer , 2020, Molecular therapy oncolytics.
[9] J. Foloppe,et al. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs , 2020, BMC Veterinary Research.
[10] P. Buracco,et al. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy , 2019, Cancer Immunology, Immunotherapy.
[11] J. Foloppe,et al. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism , 2019, Molecular therapy oncolytics.
[12] P. Black,et al. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. , 2019, Human gene therapy.
[13] A. Hemminki,et al. Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus , 2018, Molecular therapy oncolytics.
[14] B. Séguin,et al. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma , 2018, Viruses.
[15] O. Matveeva,et al. Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study) , 2018, Front. Vet. Sci..
[16] M. Coffey,et al. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours , 2018, Veterinary and comparative oncology.
[17] S. Russell,et al. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer , 2017, Molecular Cancer Therapeutics.
[18] L. Zitvogel,et al. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. , 2017, Cancer research.
[19] G. Daniels,et al. Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma , 2017, Clinical Cancer Research.
[20] M. Dey,et al. Immune System, Friend or Foe of Oncolytic Virotherapy? , 2017, Front. Oncol..
[21] Edward Jackson,et al. Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] H. Zeh,et al. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] C. London,et al. Dogs as a Model for Cancer. , 2016, Annual review of animal biosciences.
[24] S. Kuo,et al. Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma , 2015, BMC Cancer.
[25] J. Foloppe,et al. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment , 2015, Oncoimmunology.
[26] D. Thamm,et al. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. , 2015, Veterinary and comparative oncology.
[27] Matthew Breen,et al. Comparative oncology: what dogs and other species can teach us about humans with cancer , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.
[28] G. Linette,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Paradiso,et al. A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. , 2013, Critical reviews in oncology/hematology.
[30] M. Bloomston,et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.
[31] A. Dispenzieri,et al. Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses , 2012, Gene Therapy.
[32] Aaron Fenster,et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.
[33] E. G. Domínguez,et al. Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] R. Banerjee,et al. Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[35] J. Diallo,et al. Intelligent Design: Combination Therapy With Oncolytic Viruses. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[36] D. Sze,et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.
[37] J. Foloppe,et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus , 2008, Gene Therapy.
[38] Bo Wu,et al. [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.
[39] P. McCue,et al. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. , 2001, The Journal of urology.
[40] M. Onda,et al. Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] H. Makuuchi,et al. A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients , 2001, Cancer Chemotherapy and Pharmacology.
[42] H. Guchelaar,et al. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. , 2000, The Journal of antimicrobial chemotherapy.
[43] P. Leroy,et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. , 2000, Cancer research.
[44] H. Guchelaar,et al. Flucytosine: Correlation between Toxicity and Pharmacokinetic Parameters , 2000, Chemotherapy.
[45] E. Macewen,et al. Spontaneously Occurring Tumors of Companion Animals as Models for Human Cancer , 2000, Cancer investigation.
[46] H. Roenigk,et al. Immunotherapy of malignant melanoma with vaccinia virus. , 1974, Archives of dermatology.
[47] G. Westbury,et al. Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma , 1970, British medical journal.
[48] J. Limacher,et al. Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. , 2016, Veterinary and comparative oncology.
[50] H. M. Pinedo,et al. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma , 2004, Cancer Chemotherapy and Pharmacology.
[51] B. Reigner,et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.
[52] W. Adams,et al. Naturally occurring tumors in dogs as comparative models for cancer therapy research. , 1994, In vivo.